BACKGROUND: Few patients with metastatic colorectal cancer (mCRC) are candidates for resection of their hepatic disease. Yttrium-90 ((90)Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent (90)Y radioembolization. MATERIALS AND METHODS: Patients with unresectable mCRC with liver metastases treated at The Ohio State University were included in this analysis. Demographic data, carcinoembryonic antigen (CEA) values, observed toxicities, and information on prior therapies were collected. Response was assessed by RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. RESULTS: Twenty-four patients (median age, 63 years) were included. Of the patients, 54% had extrahepatic disease; 67% had bilobar involvement. The patients had received a median of 3 prior therapies. No objective responses were observed. Five patients had a CEA response. Median PFS and OS were 3.9 months (95% CI, 2.4-4.8 months) and 8.9 months (95% CI, 4.2-16.7 months), respectively. Patients older than 65 years had improved PFS (4.6 vs. 2.4 months) and OS (14 vs. 5.5 months) vs. younger patients, likely due to receipt of (90)Y treatment earlier in their disease course. The presence of extrahepatic disease and the absence of CEA response appeared negatively predictive of efficacy. Toxicities were expected and manageable. CONCLUSION: (90)Y radioembolization is active in select patients with refractory mCRC and with liver metastases, and is safe and well tolerated in the elderly. In patients with extensive extrahepatic disease, (90)Y should be used in combination with chemotherapy. CEA may be a predictor of efficacy.
BACKGROUND: Few patients with metastatic colorectal cancer (mCRC) are candidates for resection of their hepatic disease. Yttrium-90 ((90)Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent (90)Y radioembolization. MATERIALS AND METHODS:Patients with unresectable mCRC with liver metastases treated at The Ohio State University were included in this analysis. Demographic data, carcinoembryonic antigen (CEA) values, observed toxicities, and information on prior therapies were collected. Response was assessed by RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. RESULTS: Twenty-four patients (median age, 63 years) were included. Of the patients, 54% had extrahepatic disease; 67% had bilobar involvement. The patients had received a median of 3 prior therapies. No objective responses were observed. Five patients had a CEA response. Median PFS and OS were 3.9 months (95% CI, 2.4-4.8 months) and 8.9 months (95% CI, 4.2-16.7 months), respectively. Patients older than 65 years had improved PFS (4.6 vs. 2.4 months) and OS (14 vs. 5.5 months) vs. younger patients, likely due to receipt of (90)Y treatment earlier in their disease course. The presence of extrahepatic disease and the absence of CEA response appeared negatively predictive of efficacy. Toxicities were expected and manageable. CONCLUSION: (90)Y radioembolization is active in select patients with refractory mCRC and with liver metastases, and is safe and well tolerated in the elderly. In patients with extensive extrahepatic disease, (90)Y should be used in combination with chemotherapy. CEA may be a predictor of efficacy.
Authors: Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Ahsun Riaz; Frank H Miller; Laura M Kulik; Paul Nikolaidis; Vahid Yaghmai; Robert J Lewandowski; Mary F Mulcahy; Robert K Ryu; Kent T Sato; Ramona Gupta; Ed Wang; Talia Baker; Michael Abecassis; Al B Benson; Albert A Nemcek; Reed Omary; Riad Salem Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Bassel Atassi; Affaan K Bangash; Ammar Bahrani; Giuseppi Pizzi; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Vanessa L Gates; Mary F Mulcahy; Laura Kulik; Frank Miller; Vahid Yaghmai; Ravi Murthy; Andrew Larson; Reed A Omary; Riad Salem Journal: Radiographics Date: 2008 Jan-Feb Impact factor: 5.333
Authors: M A D Vente; M Wondergem; I van der Tweel; M A A J van den Bosch; B A Zonnenberg; M G E H Lam; A D van Het Schip; J F W Nijsen Journal: Eur Radiol Date: 2008-11-07 Impact factor: 5.315
Authors: Mary F Mulcahy; Robert J Lewandowski; Saad M Ibrahim; Kent T Sato; Robert K Ryu; Bassel Atassi; Steven Newman; Mark Talamonti; Reed A Omary; Al Benson; Riad Salem Journal: Cancer Date: 2009-05-01 Impact factor: 6.860
Authors: Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier Journal: N Engl J Med Date: 2009-04-02 Impact factor: 91.245
Authors: John L Nosher; Inaya Ahmed; Akshar N Patel; Vyacheslav Gendel; Philip G Murillo; Rebecca Moss; Salma K Jabbour Journal: J Gastrointest Oncol Date: 2015-04
Authors: Neha Bhooshan; Navesh K Sharma; Shahed Badiyan; Adeel Kaiser; Fred M Moeslein; Young Kwok; Pradip P Amin; Svetlana Kudryasheva; Michael D Chuong Journal: J Gastrointest Oncol Date: 2016-12
Authors: Andrew S Kennedy; David S Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Samir Kanani; Charles W Nutting; Fred M Moeslein; Samuel G Putnam; Steven C Rose; Michael A Savin; Sabine Schirm; Navesh K Sharma; Eric A Wang Journal: J Gastrointest Oncol Date: 2015-12
Authors: Akshat Saxena; Lourens Bester; Leonard Shan; Marlon Perera; Peter Gibbs; Baerbel Meteling; David L Morris Journal: J Cancer Res Clin Oncol Date: 2013-12-07 Impact factor: 4.553
Authors: K M Govaert; C S van Kessel; E J A Steller; B L Emmink; I Q Molenaar; O Kranenburg; R van Hillegersberg; I H M Borel Rinkes Journal: J Gastrointest Surg Date: 2014-01-29 Impact factor: 3.452
Authors: C E N M Rosenbaum; A F van den Hoven; M N G J A Braat; M Koopman; M G E H Lam; B A Zonnenberg; H M Verkooijen; M A A J van den Bosch Journal: EJNMMI Res Date: 2016-12-21 Impact factor: 3.138